# Phenoxodiol in Treating Patients With Refractory Solid Tumors

> **NCT00022295** · PHASE1 · COMPLETED · sponsor: **Kazia Therapeutics Limited** · enrollment: 36 (estimated)

## Conditions studied

- Unspecified Adult Solid Tumor, Protocol Specific

## Interventions

- **DRUG:** idronoxil

## Key facts

- **NCT ID:** NCT00022295
- **Lead sponsor:** Kazia Therapeutics Limited
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2001-08
- **Primary completion:** —
- **Final completion:** 2007-10
- **Target enrollment:** 36 (ESTIMATED)
- **Last updated:** 2013-03-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00022295

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00022295, "Phenoxodiol in Treating Patients With Refractory Solid Tumors". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT00022295. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*